Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/06/21 | $65,000,000 | Series A |
Alexandria Venture Investments Breakout Ventures Creacion Ventures KdT Ventures Northpond Ventures  Park West Asset Management Pfizer Venture Investments Section 32 Taiho Ventures Tekla Capital Management | undisclosed |
